Nathan Lee helps clients with U.S. and foreign patent prosecution and patent portfolio management.
Prior to joining the firm, Nathan attended New York University School of Law where he served as a Staff Editor of the Journal of Intellectual Property & Entertainment Law. In 2010, He received his Bachelor's Degree in Chemistry with a minor in Biology at Cornell University. Nathan also has research experience in Nanomaterials, Biomaterials, and Protein Chemistry.
Nathan worked as a summer associate at the firm in 2015 and joined the firm in 2016.
"Patent-Eligible Subject Matter and Healthy Aging Technology," Medical Device and Diagnostics Industry (MD+DI) (June 4, 2017).
Co-author, A “Substantially Equivalent” Disclosure May Satisfy the Written Description Requirement (August 16, 2019)
Co-author, Reissue Patent Claims Not “Clearly and Unequivocally” Supported in Original Patent Are Invalid (June 17, 2019)
Co-author, ATHENA DIAGNOSTICS, INC. v. MAYO COLLABORATIVE SERVICES (February 7, 2019)
Co-author, GUST, INC. v. ALPHACAP VENTURES LLC (October 1, 2018)
Co-author, XY, LLC v. TRANS OVA GENETICS, L.C. (May 24, 2018)
Co-author, ABBVIE INC. v. MEDIMMUNE LIMITED (February 5, 2018)
Author, FDA Launches 'Quik" 510(k) Review Pilot Program (October 11, 2018)
Author, Envision Healthcare to be Acquired by KKR for $9.9B (July 17, 2018)
Author, FDA Approves Blood Test for Concussion (March 16, 2018)